COMMUNIQUÉS West-GlobeNewswire

Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13/11/2018
Lead candidate pepinemab (VX15) being evaluated in three ongoing clinical trials in cancer and Huntington’s Disease Enrollment in CLASSICAL Lung Cancer trial and Cohort B of the SIGNAL Huntington’s Disease trial is On- [...]
Inovalon Announces 2018 Investor Day
13/11/2018
BOWIE, Md., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading technology company providing advanced, cloud-based platforms empowering data-driven healthcare, today announced that it will host an [...]
ProMIS Neurosciences Announces Third Quarter 2018 Results
13/11/2018
TORONTO and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting [...]
Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
13/11/2018
SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial results for the three and [...]
Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis
13/11/2018
Company on track to initiate Phase III trials in late November NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products [...]
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018
13/11/2018
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of [...]
TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment
13/11/2018
First dose cohort fully enrolled First patient enrolled with relapsed/refractory Mantle Cell Lymphoma achieved Partial Response (PR) to lowest dose being tested NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- TG [...]
Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation
13/11/2018
BEVERLY, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is presenting a scientific [...]
Tetra Bio-Pharma Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs
13/11/2018
Tetra Clarifies Estimated Fair Market Value of North Bud Farms Shares ORLEANS, Ontario, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE [...]
KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
13/11/2018
KP879 is being developed with serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate, to address a critical unmet need in the treatment of problematic stimulant abuse CELEBRATION, Fla., Nov. 13, 2018 (GLOBE [...]
Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
13/11/2018
Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in humans Plan to announce data from interim analysis [...]
U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome
13/11/2018
Intended for U.S. Audience U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX ® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome Seeking approval for the potential use of [...]
MediWound Reports Third Quarter 2018 Financial Results
13/11/2018
Awarded additional BARDA contract valued up to $43 Million for the development of NexoBrid ® for sulfur mustard injuries Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 13, 2018 (GLOBE [...]
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
13/11/2018
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (FRANKFURT: BTI) (OTCQB: [...]
VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20
13/11/2018
TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]
Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights
13/11/2018
Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to October Conference call and webcast to be held today at 8:00 a.m. Eastern Time [...]
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13/11/2018
CAMBRIDGE, Mass., and BEIJING, China, Nov. 13, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
How Sentara Healthcare is Removing Boundaries through PACS Modernization with Client Outlook and Mach7
13/11/2018
WATERLOO, Ontario, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Client Outlook Inc. and Mach7 Technologies (Mach7) announced today they have been selected to spearhead Sentara Healthcare’s PACS Modernization project. This [...]
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
13/11/2018
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy [...]

Pages